Robert W. Overell, PhD
President and CEO
Robert Overell is President and CEO of PhaseRx, which he founded to address the commercial need for effective siRNA delivery.
He brings over 20 years of operational and venture investment experience to bear on
this challenge. From 1997 until 2005 he was a General Partner with Frazier Healthcare
Ventures where he participated in raising over $600M of venture capital and invested over
$60M in private venture-backed biotechnology companies. His venture experience spans the
spectrum of investment risks and stages, from seed to late stage investing. He was a key
figure in the founding and/or growth of several venture-backed companies, including Array
Biopharma (NASDAQ:ARRY), and XenoPort (NASDAQ:XNPT). His investments included therapeutics,
tools, reagents, instrumentation, bioinformatics and service businesses.
Dr. Overell joined Immunex in 1984, where he built and led research and development
programs in cell and molecular biology. At Immunex, he led the development, manufacturing
and clinical affairs for the frst HIV gene therapy trial in the world, which was approved
in 1991. Dr. Overell helped found the Immunex gene therapy spinout Targeted Genetics, where
he directed the development of novel gene delivery vehicles from 1992 to 1996.
Dr. Overell was trained as a cell and molecular biologist and has published numerous
publications and patents, including a landmark paper on cell transformation in Nature
in 1983. He obtained his PhD in Biochemistry from the Institute of Cancer Research,
University of London, UK, and his BS in Biological Sciences from the University of Newcastle-upon-Tyne.
He has served on numerous corporate boards, including SkeleTech, Array Biopharma (NASDAQ:ARRY),
FastTrack, Chimerix, Quantum Dot,Inpharos, Gene Machines, and XenoPort (NASDAQ:XNPT).
He also serves on the board and is the immediate past Chairman of YouthCare (see www.youthcare.org).